Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135600 | 0.95 | MAPT (0.36) | MAPTHTR7TRPV1KCNH2THRB | |
| SCHEMBL4011698 | 0.90 | DAO (0.31) | HTR7 | |
| SCHEMBL4006254 | 0.82 | IGLV6-57 (0.34) | — | |
| SCHEMBL4767465 | 0.74 | MAPT (0.51) | MAPTTDP1TRPV1ALDH1A1KDM4E | |
| SCHEMBL3217368 | 0.74 | ALDH1A1 (0.38) | MAPTTP53TDP1TSHRALDH1A1 | |
| SCHEMBL14149934 | 0.74 | MAPT (0.47) | MAPTTP53TSHRALDH1A1KDM4E | |
| SCHEMBL6494047 | 0.73 | ALDH1A1 (0.41) | MAPTLMNATP53TDP1TSHR | |
| SCHEMBL4130557 | 0.71 | MAPT (0.66) | MAPTTDP1TRPV1ALDH1A1KDM4E | |
| SCHEMBL14149522 | 0.71 | MAPT (0.45) | MAPTHTR7TSHRKDRTRPV1 | |
| SCHEMBL18598911 | 0.70 | MAPT (0.41) | MAPTLMNATP53TDP1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| CN-1335847-A | Sulfonamide compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | MAPT 4144/4885HTR7 3510/4885LMNA 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.